Microprecipitation of nanoparticulate pharmaceutical agents using surface active material derived from similar pharmaceutical agents
February 10, 2015. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent ReferencesInjectable compositions, nanoparticles useful therein, and process of manufacturing same Chemical compounds Contrast agent for radiography Triiodoisophthalamide X-ray contrast agent Process for preparing biodegradable submicroscopic particles containing a biologically active substance and their use Process for the preparation of activated pharmaceutical compositions Crystallized carbohydrate matrix for biologically active substances, a process of preparing said matrix, and the use thereof Microdroplets of water-insoluble drugs and injectable formulations containing same Method for making uniformly sized particles from water-insoluble organic compounds 5118528 InventorsApplicationNo. 370928 filed on 01/10/1995US Classes:424/489, Particulate form (e.g., powders, granules, beads, microcapsules, and pellets)424/9.1, IN VIVO DIAGNOSIS OR IN VIVO TESTING424/9.4, X-ray contrast imaging agent (e.g., computed tomography, angiography, etc.)424/490Coated (e.g., microcapsules)ExaminersPrimary: Page, Thurman K.Assistant: Benston, William E. Jr. Attorney, Agent or FirmInternational ClassA61K 009/14AbstractThis invention describes the preparation of nanoparticulate pharmaceutical agent dispersion via a process that comprises the dissolution of the said pharmaceutical agent in an alkaline solution and then neutralizing the said solution with an acid in the presence of suitable surface-modifying, surface-active agents to form a fine particle dispersion of the said pharmaceutical agent. A combination of surface active surface modifying agents comprising a nonionic surface active substance and an anionic surface active material having a chemical structure which is at least on a molecular basis 75% similar to the pharmaceutical agent is used. This process is preferably followed by steps of diafiltration clean-up of the dispersion and then concentration of it to a desired level. This process of dispersion preparation leads to microcrystalline particles of Z-average diameters smaller than 400 nm as measured by photon correlation spectroscopy. Various modifications of precipitation schemes are described, many of which are suitable for large-scale manufacture of these agent dispersions.Other References
| |
